25 XP   0   0   10

DongKoo Bio&Pharma Co. Ltd
Buy, Hold or Sell?

Let's analyse Dongkoo together

PenkeI guess you are interested in DongKoo Bio&Pharma Co. Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of DongKoo Bio&Pharma Co. Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about DongKoo Bio&Pharma Co. Ltd

I send you an email if I find something interesting about DongKoo Bio&Pharma Co. Ltd.

Quick analysis of Dongkoo (30 sec.)










What can you expect buying and holding a share of Dongkoo? (30 sec.)

How much money do you get?

How much money do you get?
₩0.15
When do you have the money?
1 year
How often do you get paid?
55.0%

What is your share worth?

Current worth
₩3,848.19
Expected worth in 1 year
₩4,001.02
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
₩364.31
Return On Investment
6.7%

For what price can you sell your share?

Current Price per Share
₩5,400.00
Expected price per share
₩4,982 - ₩6,400
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Dongkoo (5 min.)




Live pricePrice per Share (EOD)

₩5,400.00

Intrinsic Value Per Share

₩-18,396.20 - ₩-22,316.90

Total Value Per Share

₩-14,548.01 - ₩-18,468.71

2. Growth of Dongkoo (5 min.)




Is Dongkoo growing?

Current yearPrevious yearGrowGrow %
How rich?$74.4m$69.8m$2.6m3.7%

How much money is Dongkoo making?

Current yearPrevious yearGrowGrow %
Making money$1.1m$1.4m-$276.1k-23.1%
Net Profit Margin3.3%4.5%--

How much money comes from the company's main activities?

3. Financial Health of Dongkoo (5 min.)




4. Comparing to competitors in the Pharmaceuticals industry (5 min.)




  Industry Rankings (Pharmaceuticals)  

3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Dongkoo? (5 min.)

Welcome investor! Dongkoo's management wants to use your money to grow the business. In return you get a share of Dongkoo.

What can you expect buying and holding a share of Dongkoo?

First you should know what it really means to hold a share of Dongkoo. And how you can make/lose money.

Speculation

The Price per Share of Dongkoo is ₩5,400. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Dongkoo.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Dongkoo, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩3,848.19. Based on the TTM, the Book Value Change Per Share is ₩38.21 per quarter. Based on the YOY, the Book Value Change Per Share is ₩30.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩52.87 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Dongkoo.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.030.0%0.040.0%0.050.0%0.130.0%0.150.0%
Usd Book Value Change Per Share0.040.0%0.030.0%0.020.0%0.000.0%0.130.0%
Usd Dividend Per Share0.000.0%0.040.0%0.050.0%0.040.0%0.030.0%
Usd Total Gains Per Share0.040.0%0.060.0%0.070.0%0.030.0%0.170.0%
Usd Price Per Share3.70-4.07-4.88-8.17-6.95-
Price to Earnings Ratio29.27-142.02-26.36--10,495.96--8,921.56-
Price-to-Total Gains Ratio99.45-1.61--399.49--63.61--63.61-
Price to Book Ratio1.37-1.55-1.95-1.95-1.66-
Price-to-Total Gains Ratio99.45-1.61--399.49--63.61--63.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.78
Number of shares264
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.040.04
Usd Book Value Change Per Share0.030.00
Usd Total Gains Per Share0.060.03
Gains per Quarter (264 shares)16.838.63
Gains per Year (264 shares)67.3234.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
139285738-425
2785612476-760
311785191114-1195
4156113258152-14130
5195141325190-18165
6234169392229-21200
7274198459267-25235
8313226526305-28270
9352254593343-32305
10391282660381-36340

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%16.01.00.094.1%19.01.00.095.0%19.01.00.095.0%
Book Value Change Per Share3.01.00.075.0%7.05.00.058.3%12.05.00.070.6%15.05.00.075.0%15.05.00.075.0%
Dividend per Share2.00.02.050.0%9.00.03.075.0%11.00.06.064.7%11.00.09.055.0%11.00.09.055.0%
Total Gains per Share3.01.00.075.0%8.04.00.066.7%13.04.00.076.5%16.04.00.080.0%16.04.00.080.0%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Dongkoo

About DongKoo Bio&Pharma Co. Ltd

DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral, antifungal, antihistamines, antifebrile and anti-inflammatory analgesic, respiratory system, digestant, antiplatelet, other analgesics and antipyretics, nootropics and neurotonics, nonsteroidal anti-inflammatory, and oral hypoglycemic medicines; and antiphlogisnc enzyme, ophthalmic, dermatology external, and decongestants and nasal preparations, as well as non-selective a, ß-blockers and H+ pump inhibitors. It also provides cosmetic products under the CELL BLOOM brand; and SmartX, a kit-type SVF separation medical device for use in cosmetic surgery/anti-aging clinics and medical/treatments. The company was founded in 1970 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-02-09 20:44:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of DongKoo Bio&Pharma Co. Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Dongkoo earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Dongkoo to the Pharmaceuticals industry mean.
  • A Net Profit Margin of 2.4% means that ₩0.02 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of DongKoo Bio&Pharma Co. Ltd:

  • The MRQ is 2.4%. The company is making a profit. +1
  • The TTM is 3.3%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.4%TTM3.3%-1.0%
TTM3.3%YOY4.5%-1.2%
TTM3.3%5Y6.6%-3.3%
5Y6.6%10Y7.8%-1.2%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4%8.0%-5.6%
TTM3.3%9.5%-6.2%
YOY4.5%10.1%-5.6%
5Y6.6%12.1%-5.5%
10Y7.8%11.8%-4.0%
1.1.2. Return on Assets

Shows how efficient Dongkoo is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Dongkoo to the Pharmaceuticals industry mean.
  • 0.7% Return on Assets means that Dongkoo generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of DongKoo Bio&Pharma Co. Ltd:

  • The MRQ is 0.7%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.0%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.7%TTM1.0%-0.3%
TTM1.0%YOY1.3%-0.3%
TTM1.0%5Y1.8%-0.8%
5Y1.8%10Y2.3%-0.5%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7%4.4%-3.7%
TTM1.0%5.2%-4.2%
YOY1.3%5.1%-3.8%
5Y1.8%5.0%-3.2%
10Y2.3%5.8%-3.5%
1.1.3. Return on Equity

Shows how efficient Dongkoo is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Dongkoo to the Pharmaceuticals industry mean.
  • 1.2% Return on Equity means Dongkoo generated ₩0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of DongKoo Bio&Pharma Co. Ltd:

  • The MRQ is 1.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.2%TTM1.6%-0.5%
TTM1.6%YOY2.1%-0.5%
TTM1.6%5Y2.8%-1.2%
5Y2.8%10Y4.5%-1.7%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2%6.5%-5.3%
TTM1.6%8.0%-6.4%
YOY2.1%6.8%-4.7%
5Y2.8%7.4%-4.6%
10Y4.5%10.7%-6.2%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of DongKoo Bio&Pharma Co. Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Dongkoo is operating .

  • Measures how much profit Dongkoo makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Dongkoo to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of DongKoo Bio&Pharma Co. Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY9.0%-9.0%
TTM-5Y2.1%-2.1%
5Y2.1%10Y3.9%-1.7%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.1%-12.1%
TTM-11.4%-11.4%
YOY9.0%13.5%-4.5%
5Y2.1%11.1%-9.0%
10Y3.9%13.2%-9.3%
1.2.2. Operating Ratio

Measures how efficient Dongkoo is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.35 means that the operating costs are ₩1.35 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of DongKoo Bio&Pharma Co. Ltd:

  • The MRQ is 1.347. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.060. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.347TTM1.060+0.287
TTM1.060YOY0.393+0.668
TTM1.0605Y0.567+0.494
5Y0.56710Y0.671-0.104
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3471.311+0.036
TTM1.0601.311-0.251
YOY0.3931.242-0.849
5Y0.5671.241-0.674
10Y0.6711.210-0.539
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of DongKoo Bio&Pharma Co. Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Dongkoo is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 1.26 means the company has ₩1.26 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of DongKoo Bio&Pharma Co. Ltd:

  • The MRQ is 1.256. The company is just able to pay all its short-term debts.
  • The TTM is 1.292. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.256TTM1.292-0.036
TTM1.292YOY1.309-0.017
TTM1.2925Y1.529-0.237
5Y1.52910Y1.469+0.060
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2561.959-0.703
TTM1.2921.959-0.667
YOY1.3092.168-0.859
5Y1.5292.048-0.519
10Y1.4692.053-0.584
1.3.2. Quick Ratio

Measures if Dongkoo is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Dongkoo to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.46 means the company can pay off ₩0.46 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of DongKoo Bio&Pharma Co. Ltd:

  • The MRQ is 0.460. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.899. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.460TTM0.899-0.439
TTM0.899YOY1.037-0.138
TTM0.8995Y1.184-0.285
5Y1.18410Y1.084+0.100
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4601.097-0.637
TTM0.8991.317-0.418
YOY1.0371.669-0.632
5Y1.1841.702-0.518
10Y1.0841.339-0.255
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of DongKoo Bio&Pharma Co. Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Dongkoo assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Dongkoo to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.42 means that Dongkoo assets are financed with 41.7% credit (debt) and the remaining percentage (100% - 41.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of DongKoo Bio&Pharma Co. Ltd:

  • The MRQ is 0.417. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.414. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.417TTM0.414+0.003
TTM0.414YOY0.384+0.030
TTM0.4145Y0.370+0.044
5Y0.37010Y0.397-0.027
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4170.333+0.084
TTM0.4140.333+0.081
YOY0.3840.307+0.077
5Y0.3700.322+0.048
10Y0.3970.346+0.051
1.4.2. Debt to Equity Ratio

Measures if Dongkoo is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Dongkoo to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 71.4% means that company has ₩0.71 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of DongKoo Bio&Pharma Co. Ltd:

  • The MRQ is 0.714. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.707. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.714TTM0.707+0.007
TTM0.707YOY0.626+0.081
TTM0.7075Y0.592+0.115
5Y0.59210Y0.702-0.109
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7140.499+0.215
TTM0.7070.499+0.208
YOY0.6260.456+0.170
5Y0.5920.482+0.110
10Y0.7020.542+0.160
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of DongKoo Bio&Pharma Co. Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Dongkoo generates.

  • Above 15 is considered overpriced but always compare Dongkoo to the Pharmaceuticals industry mean.
  • A PE ratio of 29.27 means the investor is paying ₩29.27 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of DongKoo Bio&Pharma Co. Ltd:

  • The EOD is 29.932. Based on the earnings, the company is overpriced. -1
  • The MRQ is 29.267. Based on the earnings, the company is overpriced. -1
  • The TTM is 142.023. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD29.932MRQ29.267+0.665
MRQ29.267TTM142.023-112.757
TTM142.023YOY26.356+115.667
TTM142.0235Y-10,495.959+10,637.982
5Y-10,495.95910Y-8,921.565-1,574.394
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD29.93231.578-1.646
MRQ29.26724.306+4.961
TTM142.02323.095+118.928
YOY26.35624.103+2.253
5Y-10,495.95927.921-10,523.880
10Y-8,921.56528.455-8,950.020
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of DongKoo Bio&Pharma Co. Ltd:

  • The EOD is -14.507. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -14.185. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -13.683. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.507MRQ-14.185-0.322
MRQ-14.185TTM-13.683-0.501
TTM-13.683YOY9.562-23.245
TTM-13.6835Y15.921-29.605
5Y15.92110Y13.533+2.388
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD-14.50743.338-57.845
MRQ-14.18528.026-42.211
TTM-13.68331.298-44.981
YOY9.56229.475-19.913
5Y15.92125.820-9.899
10Y13.53326.836-13.303
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Dongkoo is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 1.37 means the investor is paying ₩1.37 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of DongKoo Bio&Pharma Co. Ltd:

  • The EOD is 1.403. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.372. Based on the equity, the company is underpriced. +1
  • The TTM is 1.553. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.403MRQ1.372+0.031
MRQ1.372TTM1.553-0.181
TTM1.553YOY1.949-0.396
TTM1.5535Y1.950-0.397
5Y1.95010Y1.658+0.293
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD1.4033.831-2.428
MRQ1.3722.327-0.955
TTM1.5532.472-0.919
YOY1.9492.936-0.987
5Y1.9503.317-1.367
10Y1.6583.878-2.220
2. Total Gains per Share
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of DongKoo Bio&Pharma Co. Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--53.09138.207+39%30.014+77%-4.819+109%192.410-72%
Book Value Per Share--3848.1943750.317+3%3589.225+7%5937.597-35%5556.427-31%
Current Ratio--1.2561.292-3%1.309-4%1.529-18%1.469-14%
Debt To Asset Ratio--0.4170.414+1%0.384+8%0.370+13%0.397+5%
Debt To Equity Ratio--0.7140.707+1%0.626+14%0.592+21%0.702+2%
Dividend Per Share---52.871-100%75.870-100%51.540-100%43.809-100%
Eps--45.10361.748-27%75.603-40%182.552-75%213.308-79%
Free Cash Flow Per Share---93.056-12.331-87%53.893-273%122.530-176%117.366-179%
Free Cash Flow To Equity Per Share---93.0565.113-1920%65.364-242%131.443-171%104.733-189%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---22316.904--------
Intrinsic Value_10Y_min---18396.200--------
Intrinsic Value_1Y_max---30.192--------
Intrinsic Value_1Y_min---28.359--------
Intrinsic Value_3Y_max---1772.032--------
Intrinsic Value_3Y_min---1657.786--------
Intrinsic Value_5Y_max---5540.891--------
Intrinsic Value_5Y_min---4998.204--------
Market Cap51861600000.000-181%145852338720.000160630941930.000-9%194045528125.000-25%186940407573.482-22%158899346437.460-8%
Net Profit Margin--0.0240.033-29%0.045-47%0.066-64%0.078-70%
Operating Margin----0%0.090-100%0.021-100%0.039-100%
Operating Ratio--1.3471.060+27%0.393+243%0.567+138%0.671+101%
Pb Ratio1.403+2%1.3721.553-12%1.949-30%1.950-30%1.658-17%
Pe Ratio29.932+2%29.267142.023-79%26.356+11%-10495.959+35963%-8921.565+30584%
Price Per Share5400.000+2%5280.0005815.000-9%6975.000-24%11677.640-55%9925.994-47%
Price To Free Cash Flow Ratio-14.507-2%-14.185-13.683-4%9.562-248%15.921-189%13.533-205%
Price To Total Gains Ratio101.712+2%99.4511.610+6075%-399.486+502%-63.611+164%-63.611+164%
Quick Ratio--0.4600.899-49%1.037-56%1.184-61%1.084-58%
Return On Assets--0.0070.010-29%0.013-47%0.018-61%0.023-70%
Return On Equity--0.0120.016-29%0.021-44%0.028-58%0.045-74%
Total Gains Per Share--53.09191.078-42%105.884-50%46.721+14%236.219-78%
Usd Book Value--74410535.96272517950.528+3%69833864.448+7%67240716.110+11%60579668.319+23%
Usd Book Value Change Per Share--0.0370.027+39%0.021+77%-0.003+109%0.135-72%
Usd Book Value Per Share--2.6942.625+3%2.512+7%4.156-35%3.889-31%
Usd Dividend Per Share---0.037-100%0.053-100%0.036-100%0.031-100%
Usd Eps--0.0320.043-27%0.053-40%0.128-75%0.149-79%
Usd Free Cash Flow---1799381.626-238445.930-87%1049863.936-271%1343538.743-234%1230850.205-246%
Usd Free Cash Flow Per Share---0.065-0.009-87%0.038-273%0.086-176%0.082-179%
Usd Free Cash Flow To Equity Per Share---0.0650.004-1920%0.046-242%0.092-171%0.073-189%
Usd Market Cap36303120.000-181%102096637.104112441659.351-9%135831869.688-25%130858285.301-22%111229542.506-8%
Usd Price Per Share3.780+2%3.6964.071-9%4.883-24%8.174-55%6.948-47%
Usd Profit--872126.8851193983.037-27%1470149.121-41%1833178.667-52%1949060.254-55%
Usd Revenue--37008401.26935300135.686+5%32743989.296+13%29211106.247+27%27525110.243+34%
Usd Total Gains Per Share--0.0370.064-42%0.074-50%0.033+14%0.165-78%
 EOD+3 -5MRQTTM+11 -23YOY+10 -255Y+10 -2510Y+6 -29

3.2. Fundamental Score

Let's check the fundamental score of DongKoo Bio&Pharma Co. Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1529.932
Price to Book Ratio (EOD)Between0-11.403
Net Profit Margin (MRQ)Greater than00.024
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.460
Current Ratio (MRQ)Greater than11.256
Debt to Asset Ratio (MRQ)Less than10.417
Debt to Equity Ratio (MRQ)Less than10.714
Return on Equity (MRQ)Greater than0.150.012
Return on Assets (MRQ)Greater than0.050.007
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of DongKoo Bio&Pharma Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.604
Ma 20Greater thanMa 505,694.500
Ma 50Greater thanMa 1005,714.221
Ma 100Greater thanMa 2005,423.666
OpenGreater thanClose5,370.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets182,216,420
Total Liabilities75,915,655
Total Stockholder Equity106,300,766
 As reported
Total Liabilities 75,915,655
Total Stockholder Equity+ 106,300,766
Total Assets = 182,216,420

Assets

Total Assets182,216,420
Total Current Assets86,203,814
Long-term Assets96,012,606
Total Current Assets
Cash And Cash Equivalents 9,812,794
Short-term Investments 12,752,117
Net Receivables 18,841,473
Inventory 41,751,723
Total Current Assets  (as reported)86,203,814
Total Current Assets  (calculated)83,158,107
+/- 3,045,707
Long-term Assets
Property Plant Equipment 43,778,673
Intangible Assets 10,686,431
Long-term Assets  (as reported)96,012,606
Long-term Assets  (calculated)54,465,104
+/- 41,547,502

Liabilities & Shareholders' Equity

Total Current Liabilities68,614,129
Long-term Liabilities7,301,526
Total Stockholder Equity106,300,766
Total Current Liabilities
Short Long Term Debt 35,500,000
Accounts payable 15,179,965
Other Current Liabilities 2,474,477
Total Current Liabilities  (as reported)68,614,129
Total Current Liabilities  (calculated)53,154,442
+/- 15,459,686
Long-term Liabilities
Long term Debt 1,447,276
Capital Lease Obligations Min Short Term Debt1,304,464
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)7,301,526
Long-term Liabilities  (calculated)2,751,741
+/- 4,549,785
Total Stockholder Equity
Retained Earnings 65,375,064
Total Stockholder Equity (as reported)106,300,766
Total Stockholder Equity (calculated)65,375,064
+/- 40,925,702
Other
Capital Stock14,232,496
Common Stock Shares Outstanding 27,624
Net Debt 27,134,482
Net Invested Capital 143,248,042
Net Working Capital 17,589,685
Property Plant and Equipment Gross 43,778,673



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302017-12-312017-09-302016-12-31
> Total Assets 
65,310,825
75,399,030
75,593,405
111,660,316
132,725,123
134,816,750
142,956,951
143,852,745
144,353,430
141,509,128
146,811,914
151,413,480
154,786,340
157,350,437
165,330,170
171,275,513
172,059,022
175,338,926
177,718,380
182,216,420
182,216,420177,718,380175,338,926172,059,022171,275,513165,330,170157,350,437154,786,340151,413,480146,811,914141,509,128144,353,430143,852,745142,956,951134,816,750132,725,123111,660,31675,593,40575,399,03065,310,825
   > Total Current Assets 
32,184,340
44,131,524
44,517,424
66,420,021
71,900,666
71,170,628
74,151,400
64,973,601
72,352,528
68,269,636
64,592,139
72,700,896
73,832,154
70,382,123
75,376,146
80,269,946
87,417,111
88,708,297
89,056,383
86,203,814
86,203,81489,056,38388,708,29787,417,11180,269,94675,376,14670,382,12373,832,15472,700,89664,592,13968,269,63672,352,52864,973,60174,151,40071,170,62871,900,66666,420,02144,517,42444,131,52432,184,340
       Cash And Cash Equivalents 
4,930,341
12,095,332
9,909,948
6,485,428
10,340,582
11,427,237
23,673,298
7,262,106
4,881,053
7,775,098
17,223,133
21,646,258
19,557,262
0
0
0
12,513,822
9,072,748
13,863,406
9,812,794
9,812,79413,863,4069,072,74812,513,82200019,557,26221,646,25817,223,1337,775,0984,881,0537,262,10623,673,29811,427,23710,340,5826,485,4289,909,94812,095,3324,930,341
       Short-term Investments 
33,000
0
0
0
0
0
0
13,408,373
24,626,424
19,801,512
8,509,877
13,278,524
12,399,203
12,871,771
9,157,741
8,991,496
22,271,203
23,272,211
14,416,957
12,752,117
12,752,11714,416,95723,272,21122,271,2038,991,4969,157,74112,871,77112,399,20313,278,5248,509,87719,801,51224,626,42413,408,37300000033,000
       Net Receivables 
15,819,888
18,349,774
21,244,838
19,754,088
20,414,702
19,124,764
18,996,313
17,955,121
17,436,311
15,432,041
16,728,737
15,975,772
16,407,719
21,777,260
20,448,871
20,758,357
18,506,700
18,263,679
20,314,576
18,841,473
18,841,47320,314,57618,263,67918,506,70020,758,35720,448,87121,777,26016,407,71915,975,77216,728,73715,432,04117,436,31117,955,12118,996,31319,124,76420,414,70219,754,08821,244,83818,349,77415,819,888
       Inventory 
10,660,337
12,896,495
12,145,790
17,060,442
17,598,619
21,090,323
23,943,247
24,492,711
24,971,060
23,373,260
21,132,125
20,984,586
24,963,664
23,783,774
26,102,546
28,865,141
31,427,792
36,318,726
37,950,130
41,751,723
41,751,72337,950,13036,318,72631,427,79228,865,14126,102,54623,783,77424,963,66420,984,58621,132,12523,373,26024,971,06024,492,71123,943,24721,090,32317,598,61917,060,44212,145,79012,896,49510,660,337
       Other Current Assets 
478,911
81,565
76,333
106,511
858,589
948,570
921,481
825,565
77,565
77,565
77,565
141,780
131,503
59,645
64,547
1,496,434
147,386
-135,614
-74,614
0
0-74,614-135,614147,3861,496,43464,54759,645131,503141,78077,56577,56577,565825,565921,481948,570858,589106,51176,33381,565478,911
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
84,641,911
86,630,629
88,661,997
96,012,606
96,012,60688,661,99786,630,62984,641,9110000000000000000
       Property Plant Equipment 
29,581,447
28,543,475
28,236,522
39,003,739
38,489,398
38,579,419
39,581,028
39,876,474
40,377,082
39,748,466
41,058,432
40,549,533
40,050,856
39,760,591
40,629,350
39,846,212
39,681,013
40,626,154
40,851,605
43,778,673
43,778,67340,851,60540,626,15439,681,01339,846,21240,629,35039,760,59140,050,85640,549,53341,058,43239,748,46640,377,08239,876,47439,581,02838,579,41938,489,39839,003,73928,236,52228,543,47529,581,447
       Long Term Investments 
2,181,369
1,598,068
1,759,147
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,759,1471,598,0682,181,369
       Intangible Assets 
1,002,442
1,023,060
975,104
1,649,671
2,000,922
2,003,288
2,061,217
2,097,568
2,080,660
2,756,256
2,867,645
2,868,819
3,047,944
3,033,147
6,030,338
6,419,069
9,010,050
10,248,827
10,348,062
10,686,431
10,686,43110,348,06210,248,8279,010,0506,419,0696,030,3383,033,1473,047,9442,868,8192,867,6452,756,2562,080,6602,097,5682,061,2172,003,2882,000,9221,649,671975,1041,023,0601,002,442
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
00010000000000000000
> Total Liabilities 
41,138,941
39,456,915
37,848,559
38,323,724
47,072,945
48,673,658
51,204,339
49,753,172
49,700,619
47,564,736
47,994,178
50,262,589
54,662,047
59,344,124
66,489,249
69,196,386
69,953,261
74,191,363
72,884,180
75,915,655
75,915,65572,884,18074,191,36369,953,26169,196,38666,489,24959,344,12454,662,04750,262,58947,994,17847,564,73649,700,61949,753,17251,204,33948,673,65847,072,94538,323,72437,848,55939,456,91541,138,941
   > Total Current Liabilities 
39,152,894
34,718,463
34,579,734
33,060,669
38,345,128
39,908,232
42,184,186
40,853,625
40,508,237
39,032,693
43,801,742
46,457,030
50,021,523
54,297,570
61,726,628
64,515,293
66,043,564
69,648,260
67,666,394
68,614,129
68,614,12967,666,39469,648,26066,043,56464,515,29361,726,62854,297,57050,021,52346,457,03043,801,74239,032,69340,508,23740,853,62542,184,18639,908,23238,345,12833,060,66934,579,73434,718,46339,152,894
       Short-term Debt 
90,000
590,000
564,532
9,882,600
14,882,600
14,882,600
14,882,600
16,000,000
18,000,000
18,000,000
18,000,000
18,000,000
18,070,359
18,000,000
33,000,000
33,000,000
33,000,000
33,000,000
35,500,000
0
035,500,00033,000,00033,000,00033,000,00033,000,00018,000,00018,070,35918,000,00018,000,00018,000,00018,000,00016,000,00014,882,60014,882,60014,882,6009,882,600564,532590,00090,000
       Short Long Term Debt 
90,000
590,000
564,532
0
0
0
0
0
0
0
0
0
0
0
0
0
33,000,000
33,000,000
35,500,000
35,500,000
35,500,00035,500,00033,000,00033,000,0000000000000000564,532590,00090,000
       Accounts payable 
8,987,323
10,532,851
9,953,767
0
0
0
0
0
0
0
0
0
11,590,579
10,492,379
11,861,867
11,781,355
14,299,534
16,657,122
12,136,434
15,179,965
15,179,96512,136,43416,657,12214,299,53411,781,35511,861,86710,492,37911,590,5790000000009,953,76710,532,8518,987,323
       Other Current Liabilities 
8,993,921
8,352,141
8,388,932
0
0
0
0
0
0
0
0
0
8,411,519
12,448,937
8,954,291
10,636,684
2,222,078
1,992,603
2,164,703
2,474,477
2,474,4772,164,7031,992,6032,222,07810,636,6848,954,29112,448,9378,411,5190000000008,388,9328,352,1418,993,921
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,909,697
4,543,104
5,217,786
7,301,526
7,301,5265,217,7864,543,1043,909,6970000000000000000
       Long term Debt Total 
0
0
0
2,644,573
5,498,835
5,433,231
5,443,279
5,344,119
5,219,006
5,088,843
808,185
818,432
770,266
773,979
808,555
741,865
754,215
714,923
649,098
0
0649,098714,923754,215741,865808,555773,979770,266818,432808,1855,088,8435,219,0065,344,1195,443,2795,433,2315,498,8352,644,573000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,322,048
1,227,650
1,536,382
1,304,464
1,304,4641,536,3821,227,6501,322,0480000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
00010000000000000000
> Total Stockholder Equity
22,045,019
35,942,116
37,744,846
73,336,591
85,652,178
86,143,093
91,752,612
94,099,572
94,652,811
93,944,392
98,817,736
101,150,891
100,124,293
98,006,313
98,840,921
102,079,127
102,105,761
101,147,562
104,834,200
106,300,766
106,300,766104,834,200101,147,562102,105,761102,079,12798,840,92198,006,313100,124,293101,150,89198,817,73693,944,39294,652,81194,099,57291,752,61286,143,09385,652,17873,336,59137,744,84635,942,11622,045,019
   Common Stock
3,414,083
3,811,403
3,811,403
4,802,000
4,802,000
4,802,000
4,802,000
4,802,000
4,802,000
14,232,496
14,232,496
14,232,496
14,232,496
14,232,496
14,232,496
14,232,496
14,232,496
14,232,496
14,232,496
0
014,232,49614,232,49614,232,49614,232,49614,232,49614,232,49614,232,49614,232,49614,232,49614,232,4964,802,0004,802,0004,802,0004,802,0004,802,0004,802,0003,811,4033,811,4033,414,083
   Retained Earnings 
10,679,017
19,952,632
21,534,743
28,628,607
41,001,591
41,503,350
46,957,675
49,199,336
49,727,098
49,021,362
53,891,639
56,239,872
57,157,746
56,629,063
57,775,938
60,883,841
61,674,743
60,548,720
64,129,168
65,375,064
65,375,06464,129,16860,548,72061,674,74360,883,84157,775,93856,629,06357,157,74656,239,87253,891,63949,021,36249,727,09849,199,33646,957,67541,503,35041,001,59128,628,60721,534,74319,952,63210,679,017
   Accumulated Other Comprehensive Income 00000000000000000000
   Capital Surplus 
0
0
0
42,569,233
42,569,233
42,569,233
42,569,233
42,569,233
42,569,233
33,138,737
33,138,737
33,138,737
33,062,642
33,062,642
33,062,642
33,062,642
33,062,642
33,062,642
33,062,642
0
033,062,64233,062,64233,062,64233,062,64233,062,64233,062,64233,062,64233,138,73733,138,73733,138,73742,569,23342,569,23342,569,23342,569,23342,569,23342,569,233000
   Treasury Stock0000000-4,062,412-2,064,626-2,064,626-2,064,626-2,064,626-2,064,626-2,064,626-2,064,626-2,064,626-2,003,723000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue201,715,061
Cost of Revenue-78,851,102
Gross Profit122,863,959122,863,959
 
Operating Income (+$)
Gross Profit122,863,959
Operating Expense-189,654,979
Operating Income12,060,082-66,791,020
 
Operating Expense (+$)
Research Development9,219,559
Selling General Administrative87,886,503
Selling And Marketing Expenses-
Operating Expense189,654,97997,106,062
 
Net Interest Income (+$)
Interest Income238,885
Interest Expense-1,685,636
Other Finance Cost-0
Net Interest Income-1,446,751
 
Pretax Income (+$)
Operating Income12,060,082
Net Interest Income-1,446,751
Other Non-Operating Income Expenses-
Income Before Tax (EBT)7,813,02712,060,082
EBIT - interestExpense = -1,685,636
6,822,760
8,508,396
Interest Expense1,685,636
Earnings Before Interest and Taxes (EBIT)-9,498,663
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax7,813,027
Tax Provision-990,267
Net Income From Continuing Ops6,822,7606,822,760
Net Income6,822,760
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1,446,751
 

Technical Analysis of Dongkoo
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Dongkoo. The general trend of Dongkoo is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Dongkoo's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of DongKoo Bio&Pharma Co. Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 5,630 < 5,860 < 6,400.

The bearish price targets are: 5,350 > 5,119 > 4,982.

Tweet this
DongKoo Bio&Pharma Co. Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of DongKoo Bio&Pharma Co. Ltd. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

DongKoo Bio&Pharma Co. Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of DongKoo Bio&Pharma Co. Ltd. The current macd is -64.50652238.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Dongkoo price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Dongkoo. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Dongkoo price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
DongKoo Bio&Pharma Co. Ltd Daily Moving Average Convergence/Divergence (MACD) ChartDongKoo Bio&Pharma Co. Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of DongKoo Bio&Pharma Co. Ltd. The current adx is 17.95.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Dongkoo shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
DongKoo Bio&Pharma Co. Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of DongKoo Bio&Pharma Co. Ltd. The current sar is 6,273.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
DongKoo Bio&Pharma Co. Ltd Daily Parabolic SAR Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of DongKoo Bio&Pharma Co. Ltd. The current rsi is 38.60. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
DongKoo Bio&Pharma Co. Ltd Daily Relative Strength Index (RSI) ChartDongKoo Bio&Pharma Co. Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of DongKoo Bio&Pharma Co. Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Dongkoo price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
DongKoo Bio&Pharma Co. Ltd Daily Stochastic Oscillator ChartDongKoo Bio&Pharma Co. Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of DongKoo Bio&Pharma Co. Ltd. The current cci is -211.78120617.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
DongKoo Bio&Pharma Co. Ltd Daily Commodity Channel Index (CCI) ChartDongKoo Bio&Pharma Co. Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of DongKoo Bio&Pharma Co. Ltd. The current cmo is -32.4672698.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
DongKoo Bio&Pharma Co. Ltd Daily Chande Momentum Oscillator (CMO) ChartDongKoo Bio&Pharma Co. Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of DongKoo Bio&Pharma Co. Ltd. The current willr is -85.18518519.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
DongKoo Bio&Pharma Co. Ltd Daily Williams %R ChartDongKoo Bio&Pharma Co. Ltd Daily Williams %R Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of DongKoo Bio&Pharma Co. Ltd.

DongKoo Bio&Pharma Co. Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of DongKoo Bio&Pharma Co. Ltd. The current atr is 180.95.

DongKoo Bio&Pharma Co. Ltd Daily Average True Range (ATR) ChartDongKoo Bio&Pharma Co. Ltd Daily Average True Range (ATR) Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of DongKoo Bio&Pharma Co. Ltd. The current obv is 39,318,949.

DongKoo Bio&Pharma Co. Ltd Daily On-Balance Volume (OBV) ChartDongKoo Bio&Pharma Co. Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of DongKoo Bio&Pharma Co. Ltd. The current mfi is 28.45.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
DongKoo Bio&Pharma Co. Ltd Daily Money Flow Index (MFI) ChartDongKoo Bio&Pharma Co. Ltd Daily Money Flow Index (MFI) Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for DongKoo Bio&Pharma Co. Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-24ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-10-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-10-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-31STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

DongKoo Bio&Pharma Co. Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of DongKoo Bio&Pharma Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.604
Ma 20Greater thanMa 505,694.500
Ma 50Greater thanMa 1005,714.221
Ma 100Greater thanMa 2005,423.666
OpenGreater thanClose5,370.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Dongkoo with someone you think should read this too:
  • Are you bullish or bearish on Dongkoo? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Dongkoo? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about DongKoo Bio&Pharma Co. Ltd

I send you an email if I find something interesting about DongKoo Bio&Pharma Co. Ltd.


Comments

How you think about this?

Leave a comment
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Stay informed about DongKoo Bio&Pharma Co. Ltd.

Receive notifications about DongKoo Bio&Pharma Co. Ltd in your mailbox!